The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions
about
Can probiotics benefit children with autism spectrum disorders?Immunomodulatory Activities of a Fungal Protein Extracted from Hericium erinaceus through Regulating the Gut Microbiota.Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease.Nutritional Adequacy of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease.Does bowel preparation for inflammatory bowel disease surgery matter?Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases.Infectious bursal disease virus infection leads to changes in the gut associated-lymphoid tissue and the microbiota composition.Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis.Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.Immunopathophysiology of inflammatory bowel disease: how genetics link barrier dysfunction and innate immunity to inflammation.Free Total Rhubarb Anthraquinones Protect Intestinal Injury via Regulation of the Intestinal Immune Response in a Rat Model of Severe Acute Pancreatitis.Extractable Bacterial Surface Proteins in Probiotic-Host Interaction.Effects of Oligosaccharides From Morinda officinalis on Gut Microbiota and Metabolome of APP/PS1 Transgenic Mice.Fecal Microbiota Transplantation Ameliorates Experimentally Induced Colitis in Mice by Upregulating AhRCommensal microbiota induces colonic barrier structure and functions that contribute to homeostasisRetinoic Acid, Leaky Gut, and Autoimmune Diseases
P2860
Q28076833-9C82150B-FF4A-4E81-8024-E1161534CDF1Q33856396-B51ABC28-A8C8-420E-B536-46347B4FE390Q38600247-D6A7505E-FE20-4E5B-85A2-EF1645D9D19EQ38616321-88B998F9-ADCC-4CE1-B824-64B2A7C8D380Q40240509-8E875D13-455C-451B-9BE8-36CB88C28D7EQ47102876-233E630F-3015-4CAE-AF83-20C3F944B8E8Q47547142-60FC7D1C-513F-41DE-84F9-6593187972CBQ47555954-EEA9195C-656E-4BC0-BE8D-E3A8D1BC61DEQ47818880-3393AA4F-6E07-49A2-8F3D-ED0E025E6133Q52552436-57010A2B-0B57-49E5-BDDB-B1033A2B27E5Q52682338-308916B1-5F32-46A8-A96C-74E8AD3BD0D8Q55001139-F09EFAE4-91ED-4156-8F36-79FC30F1D831Q55366391-8F169EE3-DCDF-442D-928A-AC77D09CCF3BQ58705341-81CFE30F-8922-4190-AB18-91BD31C80BAEQ58705556-D81E836A-04E2-43D1-B587-3DA412976543Q58801064-BA0DC20A-7D03-40A1-97D1-23213D7BC446
P2860
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The intestinal microbiome, bar ...... for new therapeutic directions
@ast
The intestinal microbiome, bar ...... for new therapeutic directions
@en
The intestinal microbiome, bar ...... for new therapeutic directions
@nl
type
label
The intestinal microbiome, bar ...... for new therapeutic directions
@ast
The intestinal microbiome, bar ...... for new therapeutic directions
@en
The intestinal microbiome, bar ...... for new therapeutic directions
@nl
prefLabel
The intestinal microbiome, bar ...... for new therapeutic directions
@ast
The intestinal microbiome, bar ...... for new therapeutic directions
@en
The intestinal microbiome, bar ...... for new therapeutic directions
@nl
P2093
P2860
P921
P356
P1476
The intestinal microbiome, bar ...... for new therapeutic directions
@en
P2093
Christopher J Damman
David L Suskind
Stephen M Vindigni
Timothy L Zisman
P2860
P304
P356
10.1177/1756283X16644242
P407
P577
2016-07-01T00:00:00Z